AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32293516 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSpan model (multicomponent, evidence‐based, system‐wide approach to suicide prevention) implemented over a 2-year period.
Number of subjects: 0
Study 35561473 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 12 weeks
Number of subjects: 23
Study 35561473 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle recommendations (control)
Number of subjects: 23
Study 35561473 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 23
Study 33230978 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐PPM
Number of subjects: 30
Study 33230978 — intervention group
Group type: COMPARATOR
Intervention: d‐PTFE
Number of subjects: 30
Study 33938568 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 0
Study 33938568 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33750351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted version of Problem Management Plus (PM+)
Number of subjects: 240
Study 33750351 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 240
Study 34242666 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes (0.4 mg, 2.4 mg, 15.8 mg nicotine/g tobacco)
Number of subjects: 775
Study 34766245 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic threat condition
Number of subjects: 0
Study 34766245 — intervention group
Group type: COMPARATOR
Intervention: Nonthreatening control condition
Number of subjects: 0
Study 33608058 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg and 1000 mg intravenous methylprednisolone (IVMP)
Number of subjects: 0
Study 33608058 — intervention group
Group type: COMPARATOR
Intervention: IVIg and placebo (sodium chloride 0.9%)
Number of subjects: 0
Study 32627605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheonwangbosimdan
Number of subjects: 22
Study 32627605 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 22
Study 35817336 — intervention group
Group type: EXPERIMENTAL
Intervention: D 0.3 μg·kg−1·h−1 dexmedetomidine
Number of subjects: 356
Study 35817336 — intervention group
Group type: EXPERIMENTAL
Intervention: D 0.4 μg·kg−1·h−1 dexmedetomidine
Number of subjects: 356
Study 35817336 — intervention group
Group type: EXPERIMENTAL
Intervention: D 0.5 μg·kg−1·h−1 dexmedetomidine
Number of subjects: 356
Study 35817336 — intervention group
Group type: EXPERIMENTAL
Intervention: D 0.6 μg·kg−1·h−1 dexmedetomidine
Number of subjects: 356
Study 35817336 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 356
Study 32993721 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 0
Study 32993721 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 0
Study 33734433 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose regimen (commencing at 25 μg)
Number of subjects: 262
Study 33734433 — intervention group
Group type: COMPARATOR
Intervention: Low-dose regimen (commencing at 12 μg)
Number of subjects: 262
Study 32583013 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine
Number of subjects: 121
Study 32583013 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg yohimbine
Number of subjects: 121
Study 32583013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 32583013 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllability groups (learn to avoid electric shocks)
Number of subjects: 121
Study 32583013 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrollability groups (no control over shock administration)
Number of subjects: 121
Study 32583013 — intervention group
Group type: COMPARATOR
Intervention: No-shock control group
Number of subjects: 121
Study 85140364 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor specific for hepatitis B (TFdL-H) administered at 15-day intervals over a 6-month period
Number of subjects: 10
Study 85140364 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor specific for hepatitis B (TFdL-H)
Number of subjects: 10
Study 85140364 — intervention group
Group type: COMPARATOR
Intervention: Untreated CAH patients
Number of subjects: 10
Study 35296379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training plus Taichi exercise
Number of subjects: 153
Study 35296379 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 153
Study 35296379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 153
Study 35296379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study 33092320 — intervention group
Group type: EXPERIMENTAL
Intervention: Carn‐βA (2.5 g L‐carnosine plus 2.5 g β‐alanine)
Number of subjects: 10
Study 33092320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 35078147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mézières method (experimental group)
Number of subjects: 20
Study 35078147 — intervention group
Group type: COMPARATOR
Intervention: Standard European treatment protocol for LBP (control group)
Number of subjects: 20
Study 33138680 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan chewing gum
Number of subjects: 36
Study 33138680 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 36
Study 34637608 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg) under fasted conditions
Number of subjects: 72
Study 34637608 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg) under fed conditions (high-fat diet)
Number of subjects: 72
Study 34637608 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban test formulation
Number of subjects: 72
Study 34637608 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban reference formulation (Xarelto)
Number of subjects: 72
Study 34272343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal High Flow (nHF) with 'rescue' CPAP backup
Number of subjects: 754
Study 34272343 — intervention group
Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (CPAP)
Number of subjects: 754
Study 34272343 — intervention group
Group type: COMPARATOR
Intervention: Nasal High Flow (nHF) as sole primary support
Number of subjects: 754
Study 32243573 — intervention group
Group type: EXPERIMENTAL
Intervention: O-R toothbrush
Number of subjects: 110
Study 32243573 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 110
Study 36174434 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin + piperine (500 mg daily)
Number of subjects: 80
Study 36174434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32460725 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination Diet (ED)
Number of subjects: 162
Study 32460725 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Diet
Number of subjects: 162
Study 32460725 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 162
Study 35838377 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate Schools mental health programme
Number of subjects: 2539
Study 35838377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2539
Study 32981068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine cream
Number of subjects: 20
Study 32981068 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone cream
Number of subjects: 20
Study 32683541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordered treatment methods based on maximum-likelihood and robust estimation
Number of subjects: 0
Study 32683541 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed robust estimation method
Number of subjects: 0
Study 32683541 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensions for nonmonotonic alternatives
Number of subjects: 0
Study 35672192 — intervention group
Group type: EXPERIMENTAL
Intervention: One additional educational session in inhaler use
Number of subjects: 64
Study 35672192 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 64
Study 33124927 — intervention group
Group type: EXPERIMENTAL
Intervention: mini Child Tourette Syndrome Impairment Scale (mini‐CTIM)
Number of subjects: 61
Study 33124927 — intervention group
Group type: EXPERIMENTAL
Intervention: Tic treatment
Number of subjects: 61
Study 33124927 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression models
Number of subjects: 61
Study 33124927 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent assessment
Number of subjects: 61
Study 32933510 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp intervention with additions of PrEP knowledge and adherence
Number of subjects: 900
Study 32933510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma and Discrimination (S&D) reduction training for clinic staff
Number of subjects: 900
Study 36041980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG) intervention
Number of subjects: 430
Study 36041980 — intervention group
Group type: COMPARATOR
Intervention: No GWG intervention (Control)
Number of subjects: 430
Study 33545022 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 104
Study 33545022 — intervention group
Group type: EXPERIMENTAL
Intervention: cPCV7
Number of subjects: 104
Study 33545022 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 104
Study 34558739 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total extraperitoneal repair technique
Number of subjects: 120
Study 34558739 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein hernia repair open technique
Number of subjects: 120
Study 32706953 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 504
Study 32706953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg twice daily)
Number of subjects: 504
Study 32706953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg twice daily) plus Azithromycin (500 mg once daily for 7 days)
Number of subjects: 504
Study 32706953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (alone or with azithromycin)
Number of subjects: 504
Study 35812431 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia in HIV-TB coinfected persons
Number of subjects: 159
Study 35812431 — intervention group
Group type: EXPERIMENTAL
Intervention: TB participants
Number of subjects: 159
Study 35812431 — intervention group
Group type: COMPARATOR
Intervention: Non-TB participants
Number of subjects: 159
Study 34031865 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cardiovascular drugs (ACE inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins)
Number of subjects: 0
Study 34031865 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotics, pulmonary vasodilators, RAAS‐related drugs, colchicine (ongoing RCTs)
Number of subjects: 0
Study 34031865 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term anti‐atherogenic therapies (statins)
Number of subjects: 0
Study 34031865 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cardiovascular drugs
Number of subjects: 0
Study 32822887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - enoxaparin sodium 20 mg (2000 IU) twice a day for 1 week postoperatively
Number of subjects: 400
Study 32822887 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (Control group)
Number of subjects: 400
Study 36355633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health chatbot (XiaoE)
Number of subjects: 148
Study 36355633 — intervention group
Group type: COMPARATOR
Intervention: E-book
Number of subjects: 148
Study 36355633 — intervention group
Group type: COMPARATOR
Intervention: General chatbot (Xiaoai)
Number of subjects: 148
Study 36355633 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability (UMUX-LITE)
Number of subjects: 148
Study 33538404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 15
Study 33538404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 32784157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone
Number of subjects: 107
Study 32784157 — intervention group
Group type: COMPARATOR
Intervention: Isotonic solution (Control)
Number of subjects: 107
Study 35433220 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Lateral (LL) position
Number of subjects: 253
Study 35433220 — intervention group
Group type: COMPARATOR
Intervention: Prone Position (PP)
Number of subjects: 253
Study 32184153 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A
Number of subjects: 12
Study 32184153 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/B
Number of subjects: 12
Study 32184153 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/C
Number of subjects: 12
Study 32184153 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/F
Number of subjects: 12
Study 32184153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 34573862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) surveillance with annual FIT and colonoscopy if fecal hemoglobin concentration is ≥10 µg/g
Number of subjects: 3788
Study 34573862 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic surveillance
Number of subjects: 3788
Study 33238964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics (17 clinics)
Number of subjects: 33
Study 33238964 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk stratification across 33 clinics
Number of subjects: 33
Study 33238964 — intervention group
Group type: EXPERIMENTAL
Intervention: Front desk identification of patients with back pain
Number of subjects: 33
Study 33238964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming process
Number of subjects: 33
Study 33238964 — intervention group
Group type: EXPERIMENTAL
Intervention: Time with clinician
Number of subjects: 33
Study 35246356 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) session during breaktime (8 minutes)
Number of subjects: 88
Study 35246356 — intervention group
Group type: COMPARATOR
Intervention: Usual breaktime (control)
Number of subjects: 88
Study 34210943 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Tool 1
Number of subjects: 52
Study 34210943 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Tool 2
Number of subjects: 52
Study 34210943 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Tool 3
Number of subjects: 52
Study 34210943 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Report of Post‐Traumatic Symptoms questionnaire
Number of subjects: 52
Study 32998732 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (once-weekly subcutaneous)
Number of subjects: 0
Study 32998732 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (once-daily oral)
Number of subjects: 0
Study 32998732 — intervention group
Group type: COMPARATOR
Intervention: Comparators (including placebo)
Number of subjects: 0
Study 32998732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35534178 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAUC-STRAT fast tool
Number of subjects: 0
Study 34237330 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels
Number of subjects: 6861
Study 33165005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks or once weekly with and without topical corticosteroids
Number of subjects: 2632
Study 33165005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2632
Study 32767806 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14
Number of subjects: 71
Study 32767806 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP-14/CHASER
Number of subjects: 71
Study 35428316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phenylephrine 1.67% and tropicamide 0.33% microdrops
Number of subjects: 93
Study 35428316 — intervention group
Group type: COMPARATOR
Intervention: Standard drops
Number of subjects: 93
Study 34220306 — intervention group
Group type: COMPARATOR
Intervention: S‐38 position (stretcher bed height 38 ± 1 cm)
Number of subjects: 16
Study 32772319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 100
Study 32772319 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 100
Study 35247964 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium (3 g/d salt) + placebo
Number of subjects: 74
Study 35247964 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-sodium (5 g/d salt) + spironolactone (SPL)
Number of subjects: 74
Study 35247964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium (3 g/d salt) + spironolactone (SPL)
Number of subjects: 74
Study 35167779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepetaprost 0.002%
Number of subjects: 196
Study 35167779 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 196
Study 35167779 — intervention group
Group type: COMPARATOR
Intervention: All sepetaprost doses
Number of subjects: 196
Study 34145564 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care Intensive Management (PIM)
Number of subjects: 3784
Study 34145564 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 3784
Study 34145564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3784
Study 32388344 — intervention group
Group type: EXPERIMENTAL
Intervention: Underfed (60% of dietary recommendations)
Number of subjects: 3
Study 32388344 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfed (200% of dietary recommendations)
Number of subjects: 3
Study 32388344 — intervention group
Group type: COMPARATOR
Intervention: Control (100% of dietary recommendations)
Number of subjects: 3
Study 33881639 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 248
Study 33881639 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 248
Study 33881639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 248
Study 33559053 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 21 days starting from day 1 in each cycle in addition to platinum-based chemotherapy
Number of subjects: 60
Study 33559053 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 60
Study 32856781 — intervention group
Group type: EXPERIMENTAL
Intervention: Accredited Healthy Workplace
Number of subjects: 1648
Study 32856781 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-accredited corporations)
Number of subjects: 1648
Study 33779716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Arterial Grafts (MAG)
Number of subjects: 2111
Study 33779716 — intervention group
Group type: COMPARATOR
Intervention: Single Arterial Grafts (SAG)
Number of subjects: 2111
Study 34235737 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analyses of common risk variants (SNPs) shared by ASD and ADHD
Number of subjects: 101724
Study 34235737 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analyses of common risk variants (SNPs) specific to each disorder
Number of subjects: 101724
Study 34235737 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional Mendelian randomization analysis
Number of subjects: 101724
Study 32381110 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposing electroacupuncture (EA) on the healthy side, sham EA on the operated side
Number of subjects: 0
Study 32381110 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated side EA, sham EA on the healthy side
Number of subjects: 0
Study 32381110 — intervention group
Group type: COMPARATOR
Intervention: Sham EA on both sides
Number of subjects: 0
Study 32381110 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35920945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spinal cord stimulation (cSCS) for 10-14 consecutive days starting within 3 days of aneurysm rupture
Number of subjects: 12
Study 32851714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement < 10 mm at hospital discharge
Number of subjects: 226
Study 32851714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement < 10 mm up to 2 weeks post discharge
Number of subjects: 226
Study 32851714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement < 10 mm up to 4 weeks post discharge
Number of subjects: 226
Study 32851714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement at 8 weeks post discharge
Number of subjects: 226
Study 32851714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement at 12 weeks post discharge
Number of subjects: 226
Study 33631742 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 172
Study 32809224 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐cell precursor ALL
Number of subjects: 97
Study 32809224 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐lineage ALL
Number of subjects: 97
Study 34168284 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85)
Number of subjects: 168
Study 34168284 — intervention group
Group type: COMPARATOR
Intervention: physician’s choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83)
Number of subjects: 168
Study 34168284 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib–dexamethasone
Number of subjects: 168
Study 33595198 — intervention group
Group type: EXPERIMENTAL
Intervention: NoiBene programme
Number of subjects: 202
Study 32539655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity psychosocial intervention
Number of subjects: 200
Study 32539655 — intervention group
Group type: COMPARATOR
Intervention: Standardized usual care
Number of subjects: 200
Study 34463842 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab
Number of subjects: 40
Study 34463842 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab with targeted retinal photocoagulation (TRP)
Number of subjects: 40